Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
In today’s blog we will share our thoughts about a recent NEJM article, entitled “A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus”.[1] Publications on SLE literally come with a book of abbreviations and definitions nowadays and are not an easy Sunday reads. Of course, there is extensive literature Continue reading TELITACICEPT IN SLE
As many in the field have said before, what we really need are antifungals with a truly novel MoA, not minor changes to well-established classes.[1] There is a shortage of new antifungals for invasive disease. Small improvements in PK will hardly move the field forward or excite investors to engage. Our current Continue reading The Antifungal Landscape – 2
The early work on the organism and the toxoid vaccine reads like the ‘Who Is Who’ of microbiology: Klebs, Loeffler, Koch, Roux, Yersin, Behring, Kitasato, Schick, and T. Smith were all involved in bringing this deadly disease under control. In those days bacteria and diseases were referred to by the Continue reading About DIPHTHERIA